Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GenSciences

Request full access

Develops drugs that focus on underserved illnesses like hemophilia, metabolic diseases, and anti-tumor fields

Changchun, ChinaFounded 1996Biotech & Life Sciences

About GenSciences

GeneScience Pharmaceuticals Co., Ltd. (GenSci) is a biopharmaceutical company established in 1996, operating as a key subsidiary of the publicly traded Changchun High-Tech Industries Group. The company was co-founded by Dr. Lei Jin, who currently serves as CEO and Chief Scientist. Dr. Jin earned a Ph.D. from the University of California and gained experience at the U.S. biomedical firm Genentech before returning to China in 1995 to establish the company with funding from Changchun High and New Tech. Headquartered in the Changchun High-Tech Development Zone, a national hub for biomedicine, GenSci leverages genetic engineering and recombinant technology to develop and manufacture its products.

GenSci's business model is centered on the research, development, manufacturing, and commercialization of genetically engineered pharmaceuticals. The company primarily serves markets in pediatric health, women's health, and wound healing, with strategic expansion into endocrinology, immunology, and oncology. A significant milestone was the 1998 launch of Jintropin®, the first recombinant human growth hormone (rhGH) in China. This product line has since expanded, making GenSci a global provider in the rhGH market. Another key achievement includes the 2014 release of Jintrolong®, recognized as the world's first long-acting growth hormone injection. The company's R&D efforts are substantial, with an investment of over RMB 2.4 billion in 2023, representing 16.48% of its revenue. GenSci has also established a global innovation hub in Shanghai to accelerate its R&D pipeline.

The company's product portfolio is diverse, featuring a range of biologics and innovative biogenerics. Core products include the Jintropin® and Jintrolong® brands of somatropin for treating growth hormone deficiencies in both pediatric and adult patients. Other notable products are Genfulin® (Molgramostim Gel) for wound healing and tissue repair, and Jinfollin®, a Follitropin injection for women's health. These products address conditions such as pediatric growth failure, Turner syndrome, and adult growth hormone deficiency. GenSci markets its products through a combination of direct sales and partnerships, with a growing global presence in regions like Southeast Asia and Central America.

Source: Dealroom company data

At a glance

Status
Operational
Founded
1996
Headquarters
Changchun, China
Employees
30
Open positions
None listed
Dealroom signal
47.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Mar 2021 $100M $400M IDG Capital · New Alliance Capital · Haitong Securities · Efung Capital —
SERIES AOther financing Mar 2021 $23M $92M New Alliance Capital · Huaige Capital · IDG Capital —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

GenSciences website traffic

Latest recorded traffic for GenSciences is 2.6K monthly website visits, up 242.1% over the last three months. GenSciences's team grew 11.1% over the past year.

Latest monthly visits2.6K 3-month web change+242.1% 1-year team growth+11.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

GenSciences in the Changchun ecosystem

Live from Dealroom

The GenSciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • IDG Capital
  • New Alliance Capital
  • Haitong Securities
  • Efung Capital
  • Haurong Rongde Asset Management
  • Huaige Capital
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China72.7%
🇺🇸 United States22.7%
🇫🇷 France4.5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about GenSciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GenSciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.